

Sergio Fazio

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6293459/publications.pdf>

Version: 2024-02-01

105
papers

8,455
citations

81900

39
h-index

48315

88
g-index

154
all docs

154
docs citations

154
times ranked

10464
citing authors

#	ARTICLE	IF	CITATIONS
1	Macrophage LRP1 (Low-Density Lipoprotein Receptor-Related Protein 1) Is Required for the Effect of CD47 Blockade on Efferocytosis and Atherogenesis” Brief Report. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2022, 42, ATVBAHA121316854.	2.4	12
2	Real-world utilization of bempedoic acid in an academic preventive cardiology practice. <i>Journal of Clinical Lipidology</i> , 2022, 16, 94-103.	1.5	16
3	Pharmacogenomic Study of Statin-Associated Muscle Symptoms in the ODYSSEY OUTCOMES Trial. <i>Circulation Genomic and Precision Medicine</i> , 2022, 15, 101161CIRCGEN121003503.	3.6	3
4	Discordant responses of plasma low-density lipoprotein cholesterol and lipoprotein(a) to alirocumab: A pooled analysis from 10 ODYSSEY Phase 3 studies. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 816-822.	1.8	21
5	Insights into the kinetics and dynamics of the furin-cleaved form of PCSK9. <i>Journal of Lipid Research</i> , 2021, 62, 100003.	4.2	9
6	Role of PAI-1 in hepatic steatosis and dyslipidemia. <i>Scientific Reports</i> , 2021, 11, 430.	3.3	50
7	Real-world utilization of pharmacotherapy with new evidence-based cardiovascular indications in an academic preventive cardiology practice. <i>American Journal of Preventive Cardiology</i> , 2021, 5, 100144.	3.0	7
8	Divergent low-density lipoprotein receptor (LDLR) linked to low VSV G-dependent viral infectivity and unique serum lipid profile in zebra finches. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	6
9	Use of commercial genetic testing to help reclassify LDL receptor variants in clinical practice: A case report. <i>Journal of Clinical Lipidology</i> , 2021, 15, 447-450.	1.5	0
10	Optimizing sodium-glucose co-transporter 2 inhibitor use in patients with heart failure with reduced ejection fraction: A collaborative clinical practice statement. <i>American Journal of Preventive Cardiology</i> , 2021, 6, 100183.	3.0	4
11	High triglyceride to HDL cholesterol ratio is associated with increased coronary heart disease among White but not Black adults. <i>American Journal of Preventive Cardiology</i> , 2021, 7, 100198.	3.0	8
12	Hepatic Sensing Loop Regulates PCSK9 Secretion in Response to Inhibitory Antibodies. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1437-1449.	2.8	13
13	The PCSK9 revolution: Current status, controversies, and future directions. <i>Trends in Cardiovascular Medicine</i> , 2020, 30, 179-185.	4.9	66
14	Preventive cardiology as a dedicated clinical service: The past, the present, and the (Magnificent) future. <i>American Journal of Preventive Cardiology</i> , 2020, 1, 100011.	3.0	9
15	Unusual responses to PCSK9 inhibitors in a clinical cohort utilizing a structured follow-up protocol. <i>American Journal of Preventive Cardiology</i> , 2020, 1, 100012.	3.0	13
16	Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Management of Dyslipidemia and Prevention of Cardiovascular Disease Algorithm “ 2020 Executive Summary. <i>Endocrine Practice</i> , 2020, 26, 1196-1224.	2.1	117
17	Progressively decreasing plasma high-density lipoprotein cholesterol levels preceding diagnosis of smoldering myeloma. <i>Journal of Clinical Lipidology</i> , 2020, 14, 293-296.	1.5	2
18	High-Density Lipoprotein Carries Markers That Track With Recovery From Stroke. <i>Circulation Research</i> , 2020, 127, 1274-1287.	4.5	26

#	ARTICLE	IF	CITATIONS
19	Lipoprotein(a) Gets Worse. <i>Circulation Research</i> , 2020, 126, 1360-1362.	4.5	0
20	Subcellular diversion of cholesterol by gain and loss of function mutations in <scp>PMP22</scp>. <i>Glia</i> , 2020, 68, 2300-2315.	4.9	11
21	Lipoprotein(a). <i>JACC Basic To Translational Science</i> , 2020, 5, 558-560.	4.1	1
22	The American journal of preventive cardiology: On a mission to help define a specialty. <i>American Journal of Preventive Cardiology</i> , 2020, 1, 100014.	3.0	0
23	Use of PCSK9 Inhibitors in Solid Organ Transplantation Recipients. <i>JACC: Case Reports</i> , 2020, 2, 396-399.	0.6	12
24	Chylomicronemia syndrome: Familial or not?. <i>Journal of Clinical Lipidology</i> , 2020, 14, 201-206.	1.5	21
25	Aggressive Treatment for Severe Forms of Familial Hypercholesterolemia. <i>Journal of the American College of Cardiology</i> , 2020, 75, 575-577.	2.8	2
26	Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. <i>European Heart Journal</i> , 2020, 41, 2313-2330.	2.2	776
27	A neutral lipid-enriched diet improves myelination and alleviates peripheral nerve pathology in neuropathic mice. <i>Experimental Neurology</i> , 2019, 321, 113031.	4.1	26
28	Preventive Cardiology as a Subspecialty of Cardiovascular Medicine. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1926-1942.	2.8	39
29	Overview of Therapeutic Approaches for Cholesterol Lowering and Attenuation of Thrombosis for Prevention of Atherothrombosis. <i>Circulation Research</i> , 2019, 124, 351-353.	4.5	9
30	Elevated Lipoprotein(a) Levels Lower ABCA1 Cholesterol Efflux Capacity. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 4793-4803.	3.6	12
31	Impact of PCSK9 inhibitors on plasma lipoprotein(a) concentrations with or without a background of niacin therapy. <i>Journal of Clinical Lipidology</i> , 2019, 13, 580-585.	1.5	16
32	PMP22 Regulates Cholesterol Trafficking and ABCA1-Mediated Cholesterol Efflux. <i>Journal of Neuroscience</i> , 2019, 39, 5404-5418.	3.6	29
33	Response by Mueller et al to Letter Regarding Article, "Deletion of Macrophage Low-Density Lipoprotein Receptor-Related Protein 1 (LRP1) Accelerates Atherosclerosis Regression and Increases C-C Chemokine Receptor Type 7 (CCR7) Expression in Plaque Macrophages". <i>Circulation</i> , 2019, 139, 1983-1984.	1.6	2
34	The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk. <i>Endocrine Reviews</i> , 2019, 40, 537-557.	20.1	262
35	Application of PCSK9 Inhibitors in Practice. <i>Circulation Research</i> , 2019, 124, 32-37.	4.5	61
36	Brief Commentary: Marijuana and Cardiovascular Disease—What Should We Tell Patients?. <i>Annals of Internal Medicine</i> , 2019, 170, 119.	3.9	9

#	ARTICLE	IF	CITATIONS
37	Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk. <i>Circulation</i> , 2019, 139, 1483-1492.	1.6	533
38	Medication-based versus target-based lipid management. <i>Journal of Diabetes</i> , 2018, 10, 789-792.	1.8	1
39	Biologic bases of residual risk of cardiovascular events: A flawed concept. <i>European Journal of Preventive Cardiology</i> , 2018, 25, 1831-1835.	1.8	8
40	CETP Inhibition Improves HDL Function but Leads to Fatty Liver and Insulin Resistance in CETP-Expressing Transgenic Mice on a High-Fat Diet. <i>Diabetes</i> , 2018, 67, 2494-2506.	0.6	20
41	Deletion of Macrophage Low-Density Lipoprotein Receptor-Related Protein 1 (LRP1) Accelerates Atherosclerosis Regression and Increases C-C Chemokine Receptor Type 7 (CCR7) Expression in Plaque Macrophages. <i>Circulation</i> , 2018, 138, 1850-1863.	1.6	71
42	Exercise is Associated With Increased Small HDL Particle Concentration and Decreased Vascular Stiffness in Rheumatoid Arthritis. <i>Journal of Clinical Rheumatology</i> , 2018, 24, 417-421.	0.9	11
43	Co-occurrence of heterozygous CREB3L3 and APOA5 nonsense variants and polygenic risk in a patient with severe hypertriglyceridemia exacerbated by estrogen administration. <i>Journal of Clinical Lipidology</i> , 2018, 12, 1146-1150.	1.5	4
44	The Evolving Future of PCSK9 Inhibitors. <i>Journal of the American College of Cardiology</i> , 2018, 72, 314-329.	2.8	162
45	Chronic kidney disease alters lipid trafficking and inflammatory responses in macrophages: effects of liver X receptor agonism. <i>BMC Nephrology</i> , 2018, 19, 17.	1.8	16
46	PCSK9. <i>Circulation Research</i> , 2018, 122, 1420-1438.	4.5	198
47	Relationship of lipoprotein(a) molar concentrations and mass according to lipoprotein(a) thresholds and apolipoprotein(a) isoform size. <i>Journal of Clinical Lipidology</i> , 2018, 12, 1313-1323.	1.5	66
48	“Taking a look under the hood” imaging the phenotypic heterogeneity of familial hypercholesterolemia. <i>Journal of Clinical Lipidology</i> , 2018, 12, 1095-1098.	1.5	2
49	Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. <i>European Heart Journal</i> , 2017, 38, 2459-2472.	2.2	2,292
50	The PCSK9 adventure “humanizing extreme LDL lowering. <i>Nature Reviews Cardiology</i> , 2017, 14, 319-320.	13.7	2
51	Discordant response of low-density lipoprotein cholesterol and lipoprotein(a) levels to monoclonal antibodies targeting proprotein convertase subtilisin/kexin type 9. <i>Journal of Clinical Lipidology</i> , 2017, 11, 667-673.	1.5	40
52	A case of severe acquired hypertriglyceridemia in a 7-year-old girl. <i>Journal of Clinical Lipidology</i> , 2017, 11, 1480-1484.	1.5	7
53	Setting the Agenda for Preventive Cardiology. <i>Circulation Research</i> , 2017, 121, 211-213.	4.5	15
54	Application of PCSK9 Inhibitors in Practice. <i>Circulation Research</i> , 2017, 121, 499-501.	4.5	26

#	ARTICLE	IF	CITATIONS
55	Threshold Effects of Circulating Angiotensin-Like 3 Levels on Plasma Lipoproteins. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 3340-3348.	3.6	29
56	PCSK9 and Atherosclerosis - Lipids and Beyond. <i>Journal of Atherosclerosis and Thrombosis</i> , 2017, 24, 462-472.	2.0	59
57	Apolipoprotein B-containing lipoproteins and atherosclerotic cardiovascular disease. <i>F1000Research</i> , 2017, 6, 134.	1.6	63
58	Loss of SPRR3 in ApoE ^{-/-} mice leads to atheroma vulnerability through Akt dependent and independent effects in VSMCs. <i>PLoS ONE</i> , 2017, 12, e0184620.	2.5	2
59	A Systematic Review of PCSK9 Inhibitors Alirocumab and Evolocumab. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2016, 22, 641-653q.	0.9	47
60	PCSK9 Association With Lipoprotein(a). <i>Circulation Research</i> , 2016, 119, 29-35.	4.5	99
61	Jnk1 Deficiency in Hematopoietic Cells Suppresses Macrophage Apoptosis and Increases Atherosclerosis in Low-Density Lipoprotein Receptor Null Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, 1122-1131.	2.4	37
62	HDL Particle Size and Functional Heterogeneity. <i>Circulation Research</i> , 2016, 119, 704-707.	4.5	19
63	Loss of Macrophage Low-Density Lipoprotein Receptor-Related Protein 1 Confers Resistance to the Antiatherogenic Effects of Tumor Necrosis Factor- α Inhibition. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, 1483-1495.	2.4	38
64	Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering. <i>Cardiovascular Research</i> , 2016, 112, 429-442.	3.8	105
65	Local effects of human PCSK9 on the atherosclerotic lesion. <i>Journal of Pathology</i> , 2016, 238, 52-62.	4.5	143
66	Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms. <i>Cardiovascular Research</i> , 2016, 110, 268-278.	3.8	84
67	From Lipids to Inflammation. <i>Circulation Research</i> , 2016, 118, 732-749.	4.5	180
68	Macrophage IKK α Deficiency Suppresses Akt Phosphorylation, Reduces Cell Survival, and Decreases Early Atherosclerosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, 598-607.	2.4	39
69	Isolevuglandin-Type Lipid Aldehydes Induce the Inflammatory Response of Macrophages by Modifying Phosphatidylethanolamines and Activating the Receptor for Advanced Glycation Endproducts. <i>Antioxidants and Redox Signaling</i> , 2015, 22, 1633-1645.	5.4	25
70	Macrophage apoA1 protects against dyslipidemia-induced dermatitis and atherosclerosis without affecting HDL. <i>Journal of Lipid Research</i> , 2015, 56, 635-643.	4.2	26
71	Residual Cardiovascular Risk in Chronic Kidney Disease: Role of High-density Lipoprotein. <i>Archives of Medical Research</i> , 2015, 46, 379-391.	3.3	42
72	Dysfunctional high-density lipoproteins in children with chronic kidney disease. <i>Metabolism: Clinical and Experimental</i> , 2015, 64, 263-273.	3.4	54

#	ARTICLE	IF	CITATIONS
73	Is it Time to Enhance Assessment of Alcohol Intake in Patients Slated for Statin Therapy?. Current Nutrition Reports, 2015, 4, 1-5.	4.3	2
74	Macrophage SR-BI mediates efferocytosis via Src/PI3K/Rac1 signaling and reduces atherosclerotic lesion necrosis. Journal of Lipid Research, 2015, 56, 1449-1460.	4.2	100
75	Atherosclerosis following renal injury is ameliorated by pioglitazone and losartan via macrophage phenotype. Atherosclerosis, 2015, 242, 56-64.	0.8	30
76	Response to Letter Regarding Article, "Proprotein Convertase Subtilisin Kexin Type 9 Promotes Intestinal Overproduction of Triglyceride-Rich Apolipoprotein B Lipoproteins Through Both Low-Density Lipoprotein Receptor-Dependent and -Independent Mechanisms" Circulation, 2015, 131, e428.	1.6	0
77	Smoking, sex, risk factors and abdominal aortic aneurysms: a prospective study of 18,782 persons aged above 65 years in the Southern Community Cohort Study. Journal of Epidemiology and Community Health, 2015, 69, 481-488.	3.7	78
78	Sex-Specific Parental Effects on Offspring Lipid Levels. Journal of the American Heart Association, 2015, 4, .	3.7	8
79	The link between lipids, statins and cancer: is there a role for cardio-oncology?. Future Cardiology, 2015, 11, 389-393.	1.2	1
80	On the function and homeostasis of PCSK9: Reciprocal interaction with LDLR and additional lipid effects. Atherosclerosis, 2015, 238, 264-270.	0.8	70
81	PMP22 Is Critical for Actin-Mediated Cellular Functions and for Establishing Lipid Rafts. Journal of Neuroscience, 2014, 34, 16140-16152.	3.6	47
82	Identification of Small Proline-Rich Repeat Protein 3 as a Novel Atheroprotective Factor That Promotes Adaptive Akt Signaling in Vascular Smooth Muscle Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 2527-2536.	2.4	11
83	Macrophage deficiency of Akt2 reduces atherosclerosis in Ldlr null mice. Journal of Lipid Research, 2014, 55, 2296-2308.	4.2	57
84	Response to Duell et al. Circulation Research, 2014, 115, e5.	4.5	0
85	The Severe Hypercholesterolemia Phenotype. Journal of the American College of Cardiology, 2014, 63, 1935-1947.	2.8	153
86	Proprotein Convertase Subtilisin Kexin Type 9 Promotes Intestinal Overproduction of Triglyceride-Rich Apolipoprotein B Lipoproteins Through Both Low-Density Lipoprotein Receptor-Dependent and -Independent Mechanisms. Circulation, 2014, 130, 431-441.	1.6	122
87	Macrophage-derived apoE2 suppresses atherosclerosis while causing lipoprotein glomerulopathy in hyperlipidemic mice. Journal of Lipid Research, 2014, 55, 2073-2081.	4.2	8
88	Loss of Plasma Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) After Lipoprotein Apheresis. Circulation Research, 2013, 113, 1290-1295.	4.5	73
89	A prospective study of statin use and mortality among 67,385 blacks and whites in the Southeastern United States. Clinical Epidemiology, 2013, 6, 15.	3.0	22
90	PCSK9, a novel target for lowering LDL cholesterol: promise and progress. Clinical Lipidology, 2012, 7, 611-615.	0.4	2

#	ARTICLE	IF	CITATIONS
91	Evidence-based Management of Lipid Disorders. <i>Clinical Lipidology</i> , 2011, 6, 143-145.	0.4	0
92	Low-Density Lipoprotein Receptor-Related Protein 1 Prevents Early Atherosclerosis by Limiting Lesional Apoptosis and Inflammatory Ly-6C ^{high} Monocytosis. <i>Circulation</i> , 2011, 124, 454-464.	1.6	66
93	Novel Domain Interaction Regulates Secretion of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Protein. <i>Journal of Biological Chemistry</i> , 2011, 286, 43054-43061.	3.4	71
94	Macrophage LRP-1 Controls Plaque Cellularity by Regulating Efferocytosis and Akt Activation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2010, 30, 787-795.	2.4	130
95	High-density lipoprotein therapeutics and cardiovascular prevention. <i>Journal of Clinical Lipidology</i> , 2010, 4, 411-419.	1.5	24
96	Fenofibrate and risk of minor amputations in diabetes. <i>Lancet, The</i> , 2009, 373, 1740-1741.	13.7	5
97	Self-Association of Human PCSK9 Correlates with Its LDLR-Degrading Activity. <i>Biochemistry</i> , 2008, 47, 1631-1639.	2.5	91
98	Deletion of Macrophage LDL Receptor-Related Protein Increases Atherogenesis in the Mouse. <i>Circulation Research</i> , 2007, 100, 670-677.	4.5	136
99	ACAT1 Deficiency Disrupts Cholesterol Efflux and Alters Cellular Morphology in Macrophages. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005, 25, 128-134.	2.4	76
100	The role of fibrates in managing hyperlipidemia: Mechanisms of action and clinical efficacy. <i>Current Atherosclerosis Reports</i> , 2004, 6, 148-157.	4.8	106
101	Apolipoprotein AI as Therapy for Atherosclerosis: Does the Future of Preventive Cardiology Include Weekly Injections of the HDL Protein?. <i>Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics</i> , 2003, 3, 436-440.	3.4	10
102	Physiological expression of macrophage apoE in the artery wall reduces atherosclerosis in severely hyperlipidemic mice. <i>Journal of Lipid Research</i> , 2002, 43, 1602-1609.	4.2	53
103	Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis. <i>Nature Medicine</i> , 2001, 7, 699-705.	30.7	616
104	Re-emergence of fibrates in the management of dyslipidemia and cardiovascular risk. <i>Current Atherosclerosis Reports</i> , 2000, 2, 29-35.	4.8	46
105	On the Relationship Between Cholesterol Lowering and Coronary Disease Event Rate. <i>Circulation</i> , 1998, 98, 2645-2646.	1.6	5